Traco evening primrose oil
This article was originally published in The Tan Sheet
Executive Summary
FDA warning letter sent March 23 chastises the company for distributing the imported product prior to receiving a "May Proceed or Release Notice" from FDA. The agency sent the warning letter to Traco after the imported product was "returned intact" to FDA's field office in Boston, the port of entry for the product. In an April 6 letter, Traco asserted that because the product was returned "intact, . . . the alleged violation did not occur" and the warning letter "should not have been issued." Sampling was completed to FDA's satisfaction and a "May Proceed" notice is expected soon, Traco said. Reportedly, Traco agreed to market EPO only as a single ingredient at FDA's request.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning